search
Back to results

Feasibility and Acceptability Followed by Effectiveness of bCPAP for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia

Primary Purpose

Severe Pneumonia

Status
Completed
Phase
Not Applicable
Locations
Bangladesh
Study Type
Interventional
Intervention
Bubble CPAP
Low flow oxygen
Sponsored by
International Centre for Diarrhoeal Disease Research, Bangladesh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Severe Pneumonia focused on measuring Bubble CPAP, Young Children, Severe Pneumonia, Hypoxemia, Treatment failure, Mortality

Eligibility Criteria

1 Month - 59 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age between 1 month and 59 months,
  • Meet WHO clinical criteria for severe pneumonia with hypoxemia.
  • Oxygen saturation <90% despite standard flow oxygen therapy
  • Parent/guardian gives informed consent to participate in the study

Exclusion Criteria:

  • Known congenital heart disease, asthma, or upper -airway obstruction
  • Tracheostomy
  • Pneumothorax
  • Needs mechanical ventilation for any specific reason as decided by the clinician

Sites / Locations

  • International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Bubble CPAP

Low flow oxygen

Arm Description

6 hospitals will be selected randomly for this arm

6 hospitals will be selected for low flow oxygen therapy

Outcomes

Primary Outcome Measures

For stage I and II feasibility and acceptability of bubble CPAP in two tertiary and two district hospitals will be measured in number and reported in percentage
Patient level and health professional level challenge is the outcome of phase I and II. All will be measured in number and reported in percentage. For stage I and II: Primary outcome: operational challenges that may include availability of pulse oxymetry, IV cannula, IV antibiotics, oxygen supply system and nasal catheters for treating severe pneumonia Secondary outcomes: prevalence of severe pneumonia associated hypoxemia, their treatment practices, adverse events, mortality and treatment failure
For stage III: Primary outcome: Treatment failure
According to this protocol treatment failure will be declared if the following criteria are met: A. Presence of severe hypoxemia (SpO2<85%) at any time after at least one hour of intervention plus severe respiratory distress when the child is receiving BCPAP/LF OR, B. If the patient developed the indication of mechanical ventilation when the child is receiving BCPAP/LF OR, C. If the patient died during hospitalization OR, D. If the patient left against medical advice (LAMA) due to lack of improvement or deterioration of the child during hospitalization All will be measured in number and reported in percentage.

Secondary Outcome Measures

Secondary outcomes: • Death • Adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration pneumonia ) encountered
All will be measured in number and reported in percentage.

Full Information

First Posted
March 6, 2019
Last Updated
August 3, 2023
Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
Armauer Hansen Research Institute (AHRI), Ethiopia
search

1. Study Identification

Unique Protocol Identification Number
NCT03870243
Brief Title
Feasibility and Acceptability Followed by Effectiveness of bCPAP for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia
Official Title
Feasibility and Acceptability Followed by Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
September 2, 2019 (Actual)
Primary Completion Date
July 27, 2022 (Actual)
Study Completion Date
July 27, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
Armauer Hansen Research Institute (AHRI), Ethiopia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Principal Investigator: Mohammod Jobayer Chisti Research Protocol Title: Feasibility and Acceptability Followed by Effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) for Treatment of Children aged 1-59 months with Severe Pneumonia in Ethiopia: A Cluster Randomized Controlled Clinical Trial Proposed start date: 1st July 2018, Estimated end date: 31st December 2022 Background: Feasibility and acceptability followed by effectiveness of bubble continuous positive airway pressure (CPAP) were not evaluated in childhood severe pneumonia in developing countries at a larger scale. Objectives: Stages I and II To assess the feasibility and acceptability (not only by patients' care-givers but also by physicians and nurses) of bubble CPAP in treating childhood severe pneumonia in two tertiary hospitals in Stage I and in two district hospitals in Stage II To record adverse events following use of bubble CPAP in these settings To understand how much resource and time are needed to institutionalize and maintain bubble CPAP as a routine practice in the health system Stage III: To determine therapeutic efficacy/effectiveness of bubble CPAP compared to WHO standard low flow oxygen in reducing treatment failure in children admitted to hospitals with severe pneumonia and hypoxemia To determine therapeutic effectiveness of bubble CPAP compared to WHO standard low flow oxygen in reducing treatment failure & mortality in children aged 1-12 months admitted to hospitals with severe pneumonia and hypoxemia To record adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration pneumonia) encountered.
Detailed Description
Methodology: Cluster randomized controlled clinical trial Methodology: Stages I and II: Feasibility/demonstration stage will be done as an internal pilot in 3 hospitals a. Current treatment practice, facilities, and operational challenges will be evaluated for the introduction, clinical use and maintenance of bubble CPAP Stage III: Implementation of bubble CPAP will be done in 12 hospitals a. It will be done following a cluster randomized design Data collection-socio-demographic and clinical data will be collected using structured questionnaire by trained nurses and physicians. Research Site: St. Paulos Millennium Medical College, Yekatit 12 and Tikur Anbessa Specialized hospitals, 14 district hospitals Number of Participants/Patients: Stage I-30 children in each tertiary hospital (this stage has completed and we enrolled 49 children from two tertiary hospitals; these 49 enrolled children took double of our anticipated time {4 months}) Stage II- 20 children in each general hospital (2 general/district hospitals, we have enrolled total 40 children from this two hospitals from January 2020 to July 2020, which included COVID-19 period) Stage III-1240 children in 12 general/district hospitals (620 in bubble CPAP arm and 620 in WHO standard low flow arm; each hospital will be the cluster and 6 will be randomized to each arm) Main Inclusion Criteria: Age between 1 month and 59 months Meet WHO clinical criteria for severe pneumonia with hypoxemia Hypoxemia (Oxygen saturation <90% in room air) Parent/guardian gives informed consent to participate in the study Statistical Analysis: STATA -14: for initial two phases descriptive analysis of level of feasibility and acceptability will be performed For the phase III: We shall follow the principle of intention to treat. --Treatment failure and/or death will be analyzed using χ² or Fisher's exact tests as appropriate. Primary and secondary outcomes will be compared by calculating relative risks (RRs) and their 95% confidence intervals. Log-linear binomial regression will be applied to adjust for covariates to evaluate the true impact of bubble CPAP in evaluating primary and secondary outcomes and to adjust for baseline differences. Continuous variables will be analyzed using the Student t-test or the Mann-Whitney test as appropriate. Study Duration: 48 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Severe Pneumonia
Keywords
Bubble CPAP, Young Children, Severe Pneumonia, Hypoxemia, Treatment failure, Mortality

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Children aged 1-59 months with Severe Pneumonia in Ethiopia, divided in two arms; one arm will get bCPAP other arm will get WHO recommended low flow oxygen.
Masking
None (Open Label)
Masking Description
As it was an open-labeled randomized controlled clinical trial, there was no masking in any intervention.
Allocation
Randomized
Enrollment
1240 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bubble CPAP
Arm Type
Active Comparator
Arm Description
6 hospitals will be selected randomly for this arm
Arm Title
Low flow oxygen
Arm Type
Active Comparator
Arm Description
6 hospitals will be selected for low flow oxygen therapy
Intervention Type
Device
Intervention Name(s)
Bubble CPAP
Intervention Description
To see the effectiveness of Bubble Continuous Positive Airway Pressure (bCPAP) in children with severe pneumonia
Intervention Type
Device
Intervention Name(s)
Low flow oxygen
Intervention Description
To see the effectiveness of low flow oxygen in children with severe pneumonia
Primary Outcome Measure Information:
Title
For stage I and II feasibility and acceptability of bubble CPAP in two tertiary and two district hospitals will be measured in number and reported in percentage
Description
Patient level and health professional level challenge is the outcome of phase I and II. All will be measured in number and reported in percentage. For stage I and II: Primary outcome: operational challenges that may include availability of pulse oxymetry, IV cannula, IV antibiotics, oxygen supply system and nasal catheters for treating severe pneumonia Secondary outcomes: prevalence of severe pneumonia associated hypoxemia, their treatment practices, adverse events, mortality and treatment failure
Time Frame
7 months
Title
For stage III: Primary outcome: Treatment failure
Description
According to this protocol treatment failure will be declared if the following criteria are met: A. Presence of severe hypoxemia (SpO2<85%) at any time after at least one hour of intervention plus severe respiratory distress when the child is receiving BCPAP/LF OR, B. If the patient developed the indication of mechanical ventilation when the child is receiving BCPAP/LF OR, C. If the patient died during hospitalization OR, D. If the patient left against medical advice (LAMA) due to lack of improvement or deterioration of the child during hospitalization All will be measured in number and reported in percentage.
Time Frame
12-18 months (Mid April 2021 to Mid October 2022)
Secondary Outcome Measure Information:
Title
Secondary outcomes: • Death • Adverse events (pneumothorax, abdominal distension, nasal trauma, aspiration pneumonia ) encountered
Description
All will be measured in number and reported in percentage.
Time Frame
12-18 months (Mid April 2021 to Mid October 2022)
Other Pre-specified Outcome Measures:
Title
Length of hospital stay in days
Description
Length of hospital stay will be measured and reported in days.
Time Frame
12-18 months (Mid April 2021 to Mid October 2022)
Title
Incidence of nasal trauma, gastric distention, shock and air leaks in number
Description
Incidence of nasal trauma, gastric distention, shock and air leaks will be measured in number and reported in percentage.
Time Frame
12-18 months (Mid April 2021 to Mid October 2022)
Title
Duration of bCPAP in hour
Description
Duration of bCPAP will be measured and reported in hour/hours.
Time Frame
12-18 months (Mid April 2021 to Mid October 2022)
Title
Acceptability of bCPAP by nurses and physicians will be measured in number and reported in percentage
Description
Acceptability of bCPAP by nurses and physicians will be measured in number and reported in percentage.
Time Frame
12-18 months (Mid April 2021 to Mid October 2022)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
59 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age between 1 month and 59 months, Meet WHO clinical criteria for severe pneumonia with hypoxemia. Oxygen saturation <90% despite standard flow oxygen therapy Parent/guardian gives informed consent to participate in the study Exclusion Criteria: Known congenital heart disease, asthma, or upper -airway obstruction Tracheostomy Pneumothorax Needs mechanical ventilation for any specific reason as decided by the clinician
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mohammod Jobayer Chisti, PhD
Organizational Affiliation
International Centre for Diarrhoeal Disease Research, Bangladesh
Official's Role
Principal Investigator
Facility Information:
Facility Name
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
City
Dhaka
State/Province
Mohakhali
ZIP/Postal Code
1212
Country
Bangladesh

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
We will share the final outcome after completing the study
Citations:
Citation
UNICEF. Committing to Child Survival: A Promise Renewed. Progress Report 2015 2015
Results Reference
background
PubMed Identifier
25280870
Citation
Liu L, Oza S, Hogan D, Perin J, Rudan I, Lawn JE, Cousens S, Mathers C, Black RE. Global, regional, and national causes of child mortality in 2000-13, with projections to inform post-2015 priorities: an updated systematic analysis. Lancet. 2015 Jan 31;385(9966):430-40. doi: 10.1016/S0140-6736(14)61698-6. Epub 2014 Sep 30. Erratum In: Lancet. 2015 Jan 31;385(9966):420. Lancet. 2016 Jun 18;387(10037):2506.
Results Reference
background
PubMed Identifier
26361942
Citation
You D, Hug L, Ejdemyr S, Idele P, Hogan D, Mathers C, Gerland P, New JR, Alkema L; United Nations Inter-agency Group for Child Mortality Estimation (UN IGME). Global, regional, and national levels and trends in under-5 mortality between 1990 and 2015, with scenario-based projections to 2030: a systematic analysis by the UN Inter-agency Group for Child Mortality Estimation. Lancet. 2015 Dec 5;386(10010):2275-86. doi: 10.1016/S0140-6736(15)00120-8. Epub 2015 Sep 8. Erratum In: Lancet. 2015 Dec 5;386(10010):2256.
Results Reference
background
PubMed Identifier
18545737
Citation
Graham SM, English M, Hazir T, Enarson P, Duke T. Challenges to improving case management of childhood pneumonia at health facilities in resource-limited settings. Bull World Health Organ. 2008 May;86(5):349-55. doi: 10.2471/blt.07.048512.
Results Reference
background
PubMed Identifier
25378757
Citation
Rahman AE, Moinuddin M, Molla M, Worku A, Hurt L, Kirkwood B, Mohan SB, Mazumder S, Bhutta Z, Raza F, Mrema S, Masanja H, Kadobera D, Waiswa P, Bahl R, Zangenberg M, Muhe L; Persistent Diarrhoea Research Group. Childhood diarrhoeal deaths in seven low- and middle-income countries. Bull World Health Organ. 2014 Sep 1;92(9):664-71. doi: 10.2471/BLT.13.134809. Epub 2014 Jun 23.
Results Reference
background
PubMed Identifier
12818896
Citation
Duke T, Tamburlini G, Silimperi D; Paediatric Quality Care Group. Improving the quality of paediatric care in peripheral hospitals in developing countries. Arch Dis Child. 2003 Jul;88(7):563-5. doi: 10.1136/adc.88.7.563. No abstract available. Erratum In: Arch Dis Child. 2003 Oct;88(10):946.
Results Reference
background
PubMed Identifier
20522295
Citation
Duke T, Peel D, Graham S, Howie S, Enarson PM, Jacobson R. Oxygen concentrators: a practical guide for clinicians and technicians in developing countries. Ann Trop Paediatr. 2010;30(2):87-101. doi: 10.1179/146532810X12637745452356.
Results Reference
background
PubMed Identifier
20036376
Citation
McKiernan C, Chua LC, Visintainer PF, Allen H. High flow nasal cannulae therapy in infants with bronchiolitis. J Pediatr. 2010 Apr;156(4):634-8. doi: 10.1016/j.jpeds.2009.10.039. Epub 2009 Dec 29.
Results Reference
background
PubMed Identifier
21369809
Citation
Schibler A, Pham TM, Dunster KR, Foster K, Barlow A, Gibbons K, Hough JL. Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. Intensive Care Med. 2011 May;37(5):847-52. doi: 10.1007/s00134-011-2177-5. Epub 2011 Mar 3.
Results Reference
background
PubMed Identifier
24165032
Citation
Duke T. CPAP: a guide for clinicians in developing countries. Paediatr Int Child Health. 2014 Feb;34(1):3-11. doi: 10.1179/2046905513Y.0000000102. Epub 2013 Dec 6.
Results Reference
background
PubMed Identifier
26296950
Citation
Chisti MJ, Salam MA, Smith JH, Ahmed T, Pietroni MA, Shahunja KM, Shahid AS, Faruque AS, Ashraf H, Bardhan PK, Sharifuzzaman, Graham SM, Duke T. Bubble continuous positive airway pressure for children with severe pneumonia and hypoxaemia in Bangladesh: an open, randomised controlled trial. Lancet. 2015 Sep 12;386(9998):1057-65. doi: 10.1016/S0140-6736(15)60249-5. Epub 2015 Aug 19.
Results Reference
background
PubMed Identifier
19578226
Citation
Koti J, Murki S, Gaddam P, Reddy A, Reddy MD. Bubble CPAP for respiratory distress syndrome in preterm infants. Indian Pediatr. 2010 Feb;47(2):139-43. doi: 10.1007/s13312-010-0021-6. Epub 2009 May 20.
Results Reference
background
Citation
Chisti MJ, Duke T, Ahmed T, Shahunja KM, Shahid ASMSB, G. FAS, et al. The Use of Bubble CPAP and Humidified High Flow Nasal Cannula Oxygen Therapy in Children with Severe Pneumonia and Hypoxemia: A Systematic Review of the Evidence. Bangladesh Crit Care J. 2014; 2:71-8
Results Reference
background
PubMed Identifier
15858606
Citation
Liptsen E, Aghai ZH, Pyon KH, Saslow JG, Nakhla T, Long J, Steele AM, Habib RH, Courtney SE. Work of breathing during nasal continuous positive airway pressure in preterm infants: a comparison of bubble vs variable-flow devices. J Perinatol. 2005 Jul;25(7):453-8. doi: 10.1038/sj.jp.7211325.
Results Reference
background
PubMed Identifier
20393478
Citation
Courtney SE, Kahn DJ, Singh R, Habib RH. Bubble and ventilator-derived nasal continuous positive airway pressure in premature infants: work of breathing and gas exchange. J Perinatol. 2011 Jan;31(1):44-50. doi: 10.1038/jp.2010.55. Epub 2010 Apr 15.
Results Reference
background
PubMed Identifier
21262111
Citation
van den Heuvel M, Blencowe H, Mittermayer K, Rylance S, Couperus A, Heikens GT, Bandsma RH. Introduction of bubble CPAP in a teaching hospital in Malawi. Ann Trop Paediatr. 2011;31(1):59-65. doi: 10.1179/1465328110Y.0000000001.
Results Reference
background
PubMed Identifier
17766523
Citation
Buckmaster AG, Arnolda G, Wright IM, Foster JP, Henderson-Smart DJ. Continuous positive airway pressure therapy for infants with respiratory distress in non tertiary care centers: a randomized, controlled trial. Pediatrics. 2007 Sep;120(3):509-18. doi: 10.1542/peds.2007-0775. Erratum In: Pediatrics.2008 Jun;121(6): 1301.
Results Reference
background
PubMed Identifier
21442266
Citation
Kinikar A, Kulkarni R, Valvi C, Gupte N. Use of indigenous bubble CPAP during swine flu pandemic in Pune, India. Indian J Pediatr. 2011 Oct;78(10):1216-20. doi: 10.1007/s12098-011-0389-x. Epub 2011 Mar 26.
Results Reference
background
PubMed Identifier
19843596
Citation
Tagare A, Kadam S, Vaidya U, Pandit A, Patole S. A pilot study of comparison of BCPAP vs. VCPAP in preterm infants with early onset respiratory distress. J Trop Pediatr. 2010 Jun;56(3):191-4. doi: 10.1093/tropej/fmp092. Epub 2009 Oct 20.
Results Reference
background
PubMed Identifier
24760748
Citation
Daga S, Mhatre S, Borhade A, Khan D. Home-made continuous positive airways pressure device may reduce mortality in neonates with respiratory distress in low-resource setting. J Trop Pediatr. 2014 Oct;60(5):343-7. doi: 10.1093/tropej/fmu023. Epub 2014 Apr 23.
Results Reference
background
PubMed Identifier
16326752
Citation
Koyamaibole L, Kado J, Qovu JD, Colquhoun S, Duke T. An evaluation of bubble-CPAP in a neonatal unit in a developing country: effective respiratory support that can be applied by nurses. J Trop Pediatr. 2006 Aug;52(4):249-53. doi: 10.1093/tropej/fmi109. Epub 2005 Dec 2.
Results Reference
background
PubMed Identifier
22170173
Citation
Yagui AC, Vale LA, Haddad LB, Prado C, Rossi FS, Deutsch AD, Rebello CM. Bubble CPAP versus CPAP with variable flow in newborns with respiratory distress: a randomized controlled trial. J Pediatr (Rio J). 2011 Nov-Dec;87(6):499-504. doi: 10.2223/JPED.2145.
Results Reference
background
PubMed Identifier
23164308
Citation
Wilson PT, Morris MC, Biagas KV, Otupiri E, Moresky RT. A randomized clinical trial evaluating nasal continuous positive airway pressure for acute respiratory distress in a developing country. J Pediatr. 2013 May;162(5):988-92. doi: 10.1016/j.jpeds.2012.10.022. Epub 2012 Nov 16.
Results Reference
background
Citation
Federal Democratic Republic of Ethiopia Ministry of Health. Integrated Management of Newborn and Childhood Illness, Part 1 Blended Learning Module for the Health Extension Programme
Results Reference
background

Learn more about this trial

Feasibility and Acceptability Followed by Effectiveness of bCPAP for Treatment of Children Aged 1-59 Months With Severe Pneumonia in Ethiopia

We'll reach out to this number within 24 hrs